A-192621 - CAS 195529-54-5
Catalog number: 195529-54-5
Category: Inhibitor
Please be kindly noted products are not for therapeutic use. We do not sell to patients.
Molecular Formula:
C33H38N2O6
Molecular Weight:
558.675
COA:
Inquire
Targets:
Endothelin Receptor
Description:
A-192621 is a selective antagonist at endothelin ETB receptor with more effective than IRL-2500 in blocking IRL-1620-induced vasoconstriction, but both augmented constrictor responses to ET-1.
Purity:
>98%
Appearance:
Solid powder
Synonyms:
(2R,3R,4S)-4-(1,3-benzodioxol-5-yl)-1-[2-(2,6-diethylanilino)-2-oxoethyl]-2-(4-propoxyphenyl)pyrrolidine-3-carboxylic acid; (2R-(2alpha,3beta,4alpha)-4-(1,3-benzodioxol-5-yl)-1-(2-(2,6-diethylphenyl)amino)-2-oxoethyl)-2-(4-propoxyphenyl)-3-pyrrolidinecarboxylic acid; A 192621; A-192621; A192621
MSDS:
Inquire
InChIKey:
LQEHCKYYIXQEBM-FUKIBTTHSA-N
InChI:
1S/C33H38N2O6/c1-4-16-39-25-13-10-23(11-14-25)32-30(33(37)38)26(24-12-15-27-28(17-24)41-20-40-27)18-35(32)19-29(36)34-31-21(5-2)8-7-9-22(31)6-3/h7-15,17,26,30,32H,4-6,16,18-20H2,1-3H3,(H,34,36)(H,37,38)/t26-,30-,32+/m1/s1
Canonical SMILES:
CCCOC1=CC=C(C=C1)C2C(C(CN2CC(=O)NC3=C(C=CC=C3CC)CC)C4=CC5=C(C=C4)OCO5)C(=O)O
1.Change in pharmacological effect of endothelin receptor antagonists in rats with pulmonary hypertension: role of ETB-receptor expression levels.
Sauvageau S;Thorin E;Villeneuve L;Dupuis J Pulm Pharmacol Ther. 2009 Aug;22(4):311-7.
BACKGROUND AND PURPOSE: ;The endothelin (ET) system is activated in pulmonary arterial hypertension (PAH). The therapeutic value of pharmacological blockade of ET receptors has been demonstrated in various animal models and led to the current approval and continued development of these drugs for the therapy of human PAH. However, we currently incompletely comprehend what local modifications of this system occur as a consequence of PAH, particularly in small resistance arteries, and how this could affect the pharmacological response to ET receptor antagonists with various selectivities for the receptor subtypes. Therefore, the purposes of this study were to evaluate potential modifications of the pharmacology of the ET system in rat pulmonary resistance arteries from monocrotaline (MCT)-induced pulmonary arterial hypertension.;EXPERIMENTAL APPROACH: ;ET-1 levels were quantified by ELISA. PreproET-1, ETA and ETB receptor mRNA expressions were quantified in pulmonary resistance arteries using Q-PCR, while protein expression was evaluated by Western blots. Reactivity to ET-1 of isolated pulmonary resistance arteries was measured in the presence of ETA (A-147627), ETB (A-192621) and dual ETA/B (bosentan) receptor antagonists.
2.Endothelin B receptor modulates inflammatory pain and cutaneous inflammation.
Griswold DE;Douglas SA;Martin LD;Davis TG;Davis L;Ao Z;Luttmann MA;Pullen M;Nambi P;Hay DW;Ohlstein EH Mol Pharmacol. 1999 Oct;56(4):807-12.
The role of endothelin B (ET(B)) receptors in inflammation and nociception was examined using ET(B) receptor knockout mice. Genotyping studies were used with tissues from ET(B)((+/+)), ET(B)((+/-)), and ET(B)((-/-)) mice to confirm the loss of ET(B) receptors. Algesia induced by phenylbenzoquinone was evident in the (+/+) mice, reduced by approximately 80% in the (+/-) mice, and absent in the (-/-) mice. Phenylbenzoquinone-induced algesia in (+/+) mice was inhibited 74% by the ET(B) receptor-selective antagonist A192621 (25 mg/kg p.o.), but unaffected by the ET(A) receptor-selective antagonist SB 234551 (25 mg/kg p.o.). Noninflammatory pain, induced by hotplate, was equivalent between (+/+) and (-/-) mice. The cutaneous inflammatory response to topical arachidonic acid (AA) also was evaluated. Whereas (+/+) mice had a marked inflammatory response to AA, the (+/-), and (-/-) mice had significantly reduced fluid phase responses (37 and 65% inhibition, respectively). Neutrophil infiltration also was reduced in the (+/-) and (-/-) mice (51 and 65% reduction, respectively). Topical administration of A192621 (500 microg/ear) in (+/+) mice inhibited AA-induced swelling (39%), whereas SB 234551 (500 microg/ear) was without effect.
3.Role of endothelin ET(B) receptors in the renal hemodynamic and excretory responses to big endothelin-1.
Konishi F;Okada Y;Takaoka M;Gariepy CE;Yanagisawa M;Matsumura Y Eur J Pharmacol. 2002 Sep 13;451(2):177-84.
We determined the role of endothelin ET(B) receptor in the renal hemodynamic and excretory responses to big endothelin-1, using A-192621, a selective endothelin ET(B) receptor antagonist and the spotting-lethal (sl) rat, which carries a naturally occurring deletion in the endothelin ET(B) receptor gene. An intravenous injection of big endothelin-1 produced a hypertensive effect, which is greater in wild-type (+/+) rats pretreated with A-192621 and in homozygous (sl/sl) rats. Big endothelin-1 markedly increased urine flow, urinary excretion of sodium and fractional excretion of sodium in wild-type rats treated with the vehicle. These excretory responses to big endothelin-1 were markedly reduced by pharmacological endothelin ET(B) receptor blockade. On the other hand, big endothelin-1 injection to the endothelin ET(B) receptor-deficient homozygous animals resulted in a small diuretic effect. When renal perfusion pressure was protected from big endothelin-1-induced hypertension by an aortic clamp, the excretory responses in vehicle-treated wild-type rats were markedly attenuated. In homozygous or A-192621-treated wild-type rats, there was a small but significant decreasing effect in urine flow.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related Endothelin Receptor Products


CAS 123562-20-9 Endothelin 2 (human)

Endothelin 2 (human)
(CAS: 123562-20-9)

Endothelin 2 is a ligand for the endothelin (ET) receptors and a potent vasoconstrictor mainly found in the kidney and intestine.

CAS 441798-33-0 Macitentan

Macitentan
(CAS: 441798-33-0)

Macitentan is an orally available dual endothelin receptor (ETR) antagonist with potential antihypertensive and antineoplastic activity.

CAS 180384-56-9 Clazosentan

Clazosentan
(CAS: 180384-56-9)

Clazosentan, also called as AXV 034, Ro 61-1790 or VML 588, a novel endothelin A antagonist, improves cerebral blood flow and behavior after traumatic brain inj...

CAS 157212-55-0 Bosentan Hydrate

Bosentan Hydrate
(CAS: 157212-55-0)

Bosentan inhibits the presser response to big ET-1 both after i.v. and oral administration, with a long duration of action and no intrinsic agonist activity.

CAS 121695-87-2 Sarafotoxin S6c

Sarafotoxin S6c
(CAS: 121695-87-2)

Sarafotoxin S6c is a highly selective ETB endothelin receptor agonist (Ki = 0.29 and 28000 nM at ETB and ETA receptors, respectively).

CAS 556797-16-1 Macitentan n-butyl analogue

Macitentan n-butyl analogue
(CAS: 556797-16-1)

Macitentan n-butyl analogue is a derivative of Macitentan, which is an antagonist/blocker of endothelin receptors on blood vessels and smooth muscle.

CAS 153042-42-3 BMS 182874

BMS 182874
(CAS: 153042-42-3)

BMS 182874 is an endothelin receptor antagonist used as an antihypertensive agent.

T-0201 Sodium
(CAS: 188307-16-6)

The sodium salt form of T-0201 which has been found to be an Endothelin A receptor antagonist that could be used as as anti-ischaemic agent and was once studied...

Chemical Structure

CAS 195529-54-5 A-192621

Quick Inquiry

Verification code

Featured Items